FDA approves Cobenfy (xanomeline and trospium chloride), a first-In-class muscarinic agonist for the treatment of schizophrenia in adults – BMS
Bristol Myers Squibb announced that the FDA has approved Cobenfy (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults. Cobenfy represents the first… read more.
